Ascent Group LLC Has $3.21 Million Stake in Bristol Myers Squibb Company $BMY

Key Points

• Ascent Group increased its Bristol Myers Squibb stake by 46.4% in the second quarter, holding 55,716 shares valued at approximately $3.21 million. Institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb reported quarterly EPS of $2.04, exceeding estimates of $1.60, while revenue rose 5.7% year over year to $12.97 billion. The company also reaffirmed 2026 EPS guidance of $6.75–$7.00 and pays a quarterly dividend of $0.63 per share, yielding about 3.9%.
• Recent developments include FDA accelerated approval for ZENBEXUS and expanded kidney-disease research, though investors face uncertainty from a revived $6.7 billion lawsuit and unconfirmed merger speculation with AstraZeneca.

Ascent Group LLC increased its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 46.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 55,716 shares of the biopharmaceutical company's stock after purchasing an additional 17,649 shares during the quarter. Ascent Group LLC's holdings in Bristol Myers Squibb were worth $3,210,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of BMY. Swiss RE Ltd. acquired a new stake in Bristol Myers Squibb during the fourth quarter valued at approximately $25,000. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb during the second quarter worth $25,000. Physician Wealth Advisors Inc. raised its stake in Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 202 shares in the last quarter. Bayban bought a new position in shares of Bristol Myers Squibb during the fourth quarter valued at $31,000. Finally, EQ Wealth Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at $32,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The U.S. FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for multiple myeloma patients as early as first relapse. The approval is strategically important because CELMoD drugs could help extend and rejuvenate the company’s important blood-cancer franchise. Bristol Myers wins milestone FDA approval of myeloma drug acquired from Celgene
• Positive Sentiment: Zacks Research raised its Bristol Myers Squibb EPS outlook for fiscal 2027 to $6.20 from $5.93. It also increased estimates for the fourth quarter of 2026, the first and second quarters of 2027, and the first two quarters of 2028, suggesting improved analyst expectations for earnings momentum.
• Positive Sentiment: The company expanded its kidney-disease pipeline with a Phase 1 study of golcadomide, providing another potential long-term growth opportunity beyond its established oncology products. Bristol-Myers Squibb expands kidney pipeline with new golcadomide renal study
• Neutral Sentiment: Rumors of a potential AstraZeneca-Bristol Myers Squibb merger have generated investor concern. Although a transaction could create a sizable oncology-focused pharmaceutical company, the strategic, financial and execution risks remain uncertain, and no deal was confirmed. Reported AstraZeneca-Bristol Myers Squibb megamerger
• Negative Sentiment: A federal appeals court revived a $6.7 billion lawsuit alleging Bristol Myers Squibb delayed approval of drugs acquired through Celgene, including Breyanzi. The case could create substantial financial liability and legal uncertainty. Lawsuit against Bristol Myers over delayed cancer drug is revived

Bristol Myers Squibb Trading Down 1.2%

Shares of BMY opened at $63.86 on Friday. The stock's fifty day simple moving average is $59.56 and its 200-day simple moving average is $58.97. The firm has a market capitalization of $130.45 billion, a PE ratio of 14.07, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.10. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company's revenue was up 5.7% on a year-over-year basis. During the same period last year, the company earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, research analysts predict that Bristol Myers Squibb Company will post 6.96 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb's payout ratio is currently 55.51%.

Analyst Ratings Changes

Several research firms have recently weighed in on BMY. Argus raised shares of Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 target price on the stock in a report on Wednesday, August 5th. Weiss Ratings upgraded shares of Bristol Myers Squibb from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, July 30th. Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set an "overweight" rating on the stock. Truist Financial reaffirmed a "buy" rating and set a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Finally, Royal Bank Of Canada boosted their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a "sector perform" rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $66.06.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source